Sublesional Bone Loss Secondary to SCI
1 clinical trials · Condition
◉ Watch Sublesional Bone Loss Secondary to SCI
| Record | Firm | Date |
|---|---|---|
| Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (NCT04232657) | VA Office of Research and Development | 2021-03-01 |
Track Sublesional Bone Loss Secondary to SCI automatically
Every clearance here is in the API, with alerts when new ones post.